



**Visiogen, Inc. Signs Significant Financing Agreement**  
*Company Raises \$24 Million, Further Supporting its Mission and the Validity  
of the Synchrony® Dual Optic Accommodating Intraocular Lens*

IRVINE, CA., February 28, 2007—Visiogen, Inc. of Irvine, California, announced it has raised \$24 million from new and current investors in support of the Synchrony® dual optic accommodating intraocular lens. Lead investor CMEA Ventures, along with Foundation Medical Partners, made major contributions to this round of financing, which was also strongly supported by current investors Three Arch Partners, New Leaf Venture Partners and Prospect Venture Partners.

Since the last round of financing in 2003, Visiogen has consistently met all the company's timelines, received the CE Mark, and advanced into Phase III clinical trials across the United States in late 2006. "Based on the excitement generated from our ongoing clinical trials, we believe that investors see Synchrony as the next-generation product in the intraocular lens market," said Reza Zadno, president and CEO, Visiogen, Inc.

"We are excited by the potential of Visiogen's Synchrony lens to revolutionize the field of intraocular lens replacement based on the clinical results to date. We think the ophthalmology industry's reimbursement dynamics, the company's management team, and the existing investors all position this company for success," said Visiogen board member and CMEA Ventures Senior Partner Rodney D. Altman, M.D.

The team at Foundation Medical Partners reflected this sentiment as well. "We at Foundation Medical Partners believe that Visiogen's outstanding management team has developed a game-changing technology to address an important unmet clinical need in ophthalmology. We are very excited about the enormous potential for Visiogen to revolutionize the intraocular lens implant

market," said Andrew Firlik, M.D., General Partner, Foundation Medical Partners and Visiogen board member.

The proprietary Synchrony system, intended for use in cataract and refractive patients, incorporates a dual optic lens with an easy-to-use pre-loaded injector. The entire system is self-contained and ready for use without the need for lens handling. The dual optic lens can be inserted through a 3.6 – 3.8 mm clear-corneal incision. The single-piece silicone lens unfolds in the eye upon insertion and features two optics connected by a spring system. The springs connect a 5.5-mm high power anterior optic and a 6-mm negative power posterior optic; the spring action moves the front optic and changes the eye's focus from near to far. This unique combination of positive- and negative-powered optics is customized for each patient.

To date, the Synchrony lens has been implanted in over 400 patients worldwide. The company announced that it had received the European CE Mark for the Synchrony® Dual Optic Accommodating IOL in June of 2006, which allows expansion into post-marketing research studies within Europe to further build the scientific foundation for Synchrony.

###

#### **About CMEA Ventures**

CMEA Ventures is a \$771 million venture capital firm focused on life sciences, high technology, and energy & materials investments. CMEA believes that the most successful venture backed companies are science focused with experienced teams intent on winning. As a result, CMEA's portfolio companies typically have cutting edge and highly differentiated technology at their core, with founding teams of the highest caliber. Examples include CMEA Ventures early stage investments in many leading Silicon Valley companies, such as Maxygen (MAXY), Monogram Biosciences (MGRM), Symyx (SMMX), and Syrrx (purchased by Takeda.)

#### **About Foundation Medical Partners**

Foundation Medical Partners is a national venture capital investment firm formed in 2001 with the vision of bringing cutting edge clinical expertise to healthcare investments. Foundation specializes in early stage investments in the medical device, biopharmaceutical, and predictive medicine technology sectors. The firm actively manages over \$150 million in venture capital, with a current market capitalization of its healthcare investments totaling over \$2 billion. Foundation was an early venture investor in now-public companies AtriCure (NASDAQ: ATRC), Combinatorx (NASDAQ: CRXX), Immunicon (NASDAQ: IMMC), and Northstar Neuroscience (NASDAQ: NSTR), as well as a portfolio of other privately held firms, such as BioNeuronics, BridgePoint Medical, CoApt Systems, CardioNet, CardioMEMS, EndoGastric Solutions, Marinus Pharmaceuticals, and SpineWave.

**About Visiogen**

Visiogen, Inc. is focused on developing innovative products for cataract and refractive patients. Founded in Irvine, California, in 2001, Visiogen's first commercial application, Synchrony®, a dual optic accommodating intraocular lens and pre-loaded injector, is currently in clinical studies in the U.S. and recently received the CE Mark in Europe.

More information on the company and its offerings can be obtained by contacting:

Chuck Brauer or Kate Jennings

Maricich Communications for Visiogen, Inc.

Tel. 949-223-6455

Fax 949-223-6451

[kate@maricich.com](mailto:kate@maricich.com)